Sat Kartar Shopping Ltd
Incorporated in June 2012, Sat Kartar Shopping Limited is an Ayurveda healthcare company that delivers natural wellness solutions for therapeutic and lifestyle products.[1]
- Market Cap ₹ 260 Cr.
- Current Price ₹ 165
- High / Low ₹ 238 / 124
- Stock P/E 18.9
- Book Value ₹ 37.0
- Dividend Yield 0.42 %
- ROCE 39.7 %
- ROE 32.0 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 47.6%
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|
| 52 | 83 | 128 | 163 | 175 | |
| 49 | 78 | 118 | 149 | 157 | |
| Operating Profit | 3 | 5 | 10 | 14 | 19 |
| OPM % | 5% | 6% | 8% | 9% | 11% |
| 0 | 0 | 0 | 1 | 2 | |
| Interest | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 1 | 1 | 1 | 1 | 2 |
| Profit before tax | 2 | 3 | 9 | 13 | 19 |
| Tax % | 7% | 27% | 27% | 25% | |
| 1 | 3 | 6 | 10 | 14 | |
| EPS in Rs | 1.99 | 3.59 | 22.54 | 6.24 | 8.75 |
| Dividend Payout % | 0% | 0% | 3% | 11% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 46% |
| TTM: | 17% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 90% |
| TTM: | 83% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 5% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 48% |
| Last Year: | 32% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 0.70 | 0.70 | 3 | 16 | 16 |
| Reserves | 0 | 3 | 7 | 36 | 42 |
| 8 | 4 | 2 | 6 | 2 | |
| 3 | 8 | 11 | 6 | 11 | |
| Total Liabilities | 12 | 15 | 22 | 64 | 71 |
| 5 | 4 | 8 | 7 | 6 | |
| CWIP | 0 | 0 | 0 | 0 | 1 |
| Investments | 0 | 0 | 0 | 0 | 1 |
| 8 | 11 | 14 | 57 | 63 | |
| Total Assets | 12 | 15 | 22 | 64 | 71 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 7 | -5 | |||
| -3 | -0 | |||
| -3 | 34 | |||
| Net Cash Flow | 2 | 28 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 1 | 0 | 7 | 13 |
| Inventory Days | 31 | 25 | 23 | 185 |
| Days Payable | 165 | 226 | 237 | 170 |
| Cash Conversion Cycle | -134 | -200 | -208 | 29 |
| Working Capital Days | 1 | -14 | -7 | 31 |
| ROCE % | 50% | 98% | 40% |
Insights
In beta| Mar 2024 | Mar 2025 | |
|---|---|---|
| Average Ticket Size per Order INR |
|
|
| Consumer Database Size Million |
||
| Daily Unique Leads Generated Number |
||
| Number of Call / Wellness Executives Number |
||
| Number of Manufacturing Facilities (Contract/Owned) Number |
||
| Number of SKUs Number |
||
| Pincodes Covered Across India Number |
||
| Total Employee Strength Number |
||
Documents
Announcements
-
Options to purchase securities
16 March 2026 - NRC approved grant of 139,600 ESOs at Rs.10 each on March 16, 2026.
-
Committee Meeting Updates
16 March 2026 - Grant of 1,39,600 ESOPs at Rs.10 each approved March 16, 2026.
-
Monthly Business Updates
5 March 2026 - Filed monthly business update for month ended February 28, 2026; submitted March 5, 2026.
-
Commencement of commercial production/operations
5 March 2026 - 30-bed Sat Kartar Sanjeevan Hospital opened in Paschim Vihar, Delhi on March 5, 2026; investment ~Rs2.00 Cr.
-
Analysts/Institutional Investor Meet/Con. Call Updates
2 March 2026 - Virtual group meet at Bharat Connect on 6 March 2026, 10:00-11:00 AM.
Annual reports
Concalls
-
Nov 2025TranscriptPPT
-
Nov 2025Transcript PPT REC
-
Oct 2025TranscriptAI SummaryPPT
-
May 2025Transcript PPT REC
Business Model[1]
The company operates in the Ayurveda healthcare sector using a Direct-to-Consumer (D2C) model, combining Ayurvedic principles with modern research. It focuses on product innovation, branding, and marketing while outsourcing manufacturing to trusted partners, adopting an asset-light strategy.